Breadcrumb Home Business Activities Lundbeckfonden BioCapital Lundbeckfonden BioCapital Portfolio River Vision River Vision Developed a biologic to treat the orphan eye disorder Graves Orbitopathy, a very debilitating condition that ultimately can lead to blindness. Related news about River Vision Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (RV001), a Biologic in Late-Stage Development for Rare Eye Disease River Vision Announces Receipt of Breakthrough Designation from US FDA Lundbeckfonden BioCapital Invested 2012 Acquired by Horizon in 2017 Location New York, USA